Equity Transaction Chart
Viridian publishes weekly data on equity capital raises in the Cannabis/CBD/Psychedelic industries. This data includes information about the company issuing equity (public/private, state/country location), deal size, deal structure, pricing, share information, deal implied valuation, and warrant information.
This Section is Only Available to Higher Tier Memberships
Please Purchase a Premium or Enterprise membership to see more.
This Section is Only Available to Higher Tier Memberships
Please Purchase a Premium or Enterprise membership to see more.
Equity Commentary
Equity Raises:
-
- On April 15, 2025, InnoCan Pharma Corp. (INNO: CSE)(INNPF: OTCQB), a company focused on developing innovative drug delivery platform technologies based on cannabinoid science, closed a non-brokered private placement of units for gross proceeds of approximately $0.15M.
- Each unit, priced at $.129, was composed of one common share and one four-year warrant with an exercise price of $.179 (38.8% premium). The resulting net share price of $.106 was an 11.31% discount to the pre-announcement price.
- The transaction implies a market cap of $31.27M, an enterprise value of $27.89, and an EV/ annualized revenue of .95x.
Public vs. Private Raises:
- Both capital raisers this week are public. Both trade in Canada (one on TSX and one on CSE), and one trades in the U.S. (on OTC).
Equity vs. Debt Cap Raises:
- Debt accounted for 63% of trailing 8-week capital raises. The ratio may go down if companies are able to utilize favorable regulatory-induced stock price increases to complete equity issues. However, equity pricing has remained stubbornly low while the cannabis debt capital markets have reopened.
Viridian publishes weekly insights on equity capital raises in the Cannabis/CBD/Psychedelic industries. These insights typically highlight the most interesting/meaningful equity transactions of that week, and commentary on market conditions, equity deal structures and investor groups.